Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 19:16:135-148.
doi: 10.2147/CCID.S391356. eCollection 2023.

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Fabrizio Martora  1 , Matteo Megna #  1 , Teresa Battista #  1 , Luca Potestio #  1 , Maria Carmela Annunziata  1 , Claudio Marasca  1 , Alessia Villani  1 , Gabriella Fabbrocini  1
Affiliations
Review

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Fabrizio Martora et al. Clin Cosmet Investig Dermatol. .

Abstract

To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly variable. In our review, we highlighted the current evidence from literature on the use of biologics in HS in a real-life setting, particularly adalimumab, secukinumab and ustekinumab. Data on the effectiveness and safety of biologic drugs in HS management have been analyzed. Even if the results are promising, more studies are needed. In our opinion, the armamentarium of drugs for HS management is increasing, and treatment will be based on a tailored-tail approach, minimizing the risk of adverse events. In this context, we want to point out the reported effectiveness and safety data concerning adalimumab, ustekinumab and secukinumab as well as ixekizumab.

Keywords: adalimumab; guselkumab; hidradenitis suppurativa; ixekizumab; real life evidence; secukinumab; ustekinumab.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Prisma checklist.
See this image and copyright information in PMC

References

    1. Chiricozzi A, Veraldi S, Fabbrocini G, et al. The Hidradenitis Suppurativa (HS) “multidisciplinary unit”: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol. 2018;28(2):274–275. doi:10.1684/ejd.2018.3254 - DOI - PubMed
    1. Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? Skin Appendage Disord. 2022;8(3):265–268. doi:10.1159/000521712 - DOI - PMC - PubMed
    1. Jemec GB. Clinical practice Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–164. doi:10.1056/NEJMcp1014163 - DOI - PubMed
    1. Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa ?-15 years after. Exp Dermatol. 2020;29(12):1154–1170. doi:10.1111/exd.14214 - DOI - PubMed
    1. de Oliveira ASLE, Bloise G, Moltrasio C, et al. Transcriptome meta-analysis confirms the hidradenitis suppurativa pathogenic triad: upregulated inflammation, altered epithelial organization, and dysregulated metabolic signaling. Biomolecules. 2022;12(10):1371. doi:10.3390/biom12101371 - DOI - PMC - PubMed